Europe Clinical Trials Market - Growth, Trends, and Forecast (2020 - 2025)

The Europe Clinical Trials Market is segmented by Phase (Phase I, II, III, and IV), Design, and Geography.

Market Snapshot

Study Period:

2017-2025

Base Year:

2019

CAGR:

4.2 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

Factors that are responsible for the growth of the European clinical trials market include high R&D spending of the pharmaceutical industry and the increasing prevalence of diseases.

  • Another driving factor is the increasing focus on rare diseases and multiple orphan drugs in the pipeline. As rare diseases have considerably low prevalence rate, as compared to other diseases, drug manufacturers were previously not interested in developing drugs for rare diseases, due to the low earnings in this category. However, the situation has changed currently, as companies are increasingly focusing on cures for rare diseases, specifically in developed countries.
  • The push from different governments has motivated the small, medium, and large players to enter into orphan drug development. Thus, there are multiple drugs in the pipeline. Additionally, the orphan drug presents an avenue of high profit to the leading pharmaceutical companies working in a low CAGR market. As a result, Novartis, GlaxoSmithKline, and Pfizer (among others) have entered this field.

Scope of the Report

Clinical trials are the experiments conducted in clinical research, and they follow a regulated protocol. They are performed particularly to obtain data on safety and efficacy of a newly developed drug. Clinical trial data is mandatory for further approval of the drug, for it to enter the market.

By Phase
Phase I
Phase II
Phase III
Phase IV
By Design
Treatment Studies
Randomized Control Trial
Adaptive Clinical Trial
Non-randomized Control Trial
Observational Studies
Cohort Study
Case Control Study
Cross Sectional Study
Ecological Study
Geography
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Phase III Segment is Expected to hold the Major Revenue Share

Phase III is one of the most critical phases assessing the effectiveness of the new intervention, as well as its value in clinical practice. As per the EU Clinical Trials Register, a total number of 12,748 studies are currently in Phase III trials in European countries.

In phase III, the drug or the treatment is tested in large groups of people, ranging from 1,000 to 3,000 participants. These trials are conducted to confirm and expand on the safety and effectiveness results from Phase I and II trials, to compare the drug to standard therapies for the disease or condition being studied, and to evaluate the overall risks and benefits of the drug.

To understand key trends, Download Sample Report

Competitive Landscape

The European clinical trials market is competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. With the rising need for new drugs and treatments, advances in healthcare, and an increasing number of new diseases, it is expected that few smaller players will enter the market and may hold a substantial share in the near future. Some of the major players of the market are Eli Lilly and Company, Pfizer Inc., Pharmaceutical Product Development LLC, Novo Nordisk, and Sanofi, among others.

You can also purchase parts of this report. Do you want to check out a section wise price list?

Table Of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 High R&D Spending of the Pharmaceutical Industry

      2. 4.2.2 Increasing Prevalence of Diseases

      3. 4.2.3 Focus on Rare Diseases and Multiple Orphan Drugs in Pipeline

    3. 4.3 Market Restraints

      1. 4.3.1 Lower Healthcare Reimbursement in Developing Countries

      2. 4.3.2 Stringent Regulations for Patient Enrollment

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Phase

      1. 5.1.1 Phase I

      2. 5.1.2 Phase II

      3. 5.1.3 Phase III

      4. 5.1.4 Phase IV

    2. 5.2 By Design

      1. 5.2.1 Treatment Studies

        1. 5.2.1.1 Randomized Control Trial

        2. 5.2.1.2 Adaptive Clinical Trial

        3. 5.2.1.3 Non-randomized Control Trial

      2. 5.2.2 Observational Studies

        1. 5.2.2.1 Cohort Study

        2. 5.2.2.2 Case Control Study

        3. 5.2.2.3 Cross Sectional Study

        4. 5.2.2.4 Ecological Study

    3. 5.3 Geography

      1. 5.3.1 Europe

        1. 5.3.1.1 Germany

        2. 5.3.1.2 United Kingdom

        3. 5.3.1.3 France

        4. 5.3.1.4 Italy

        5. 5.3.1.5 Spain

        6. 5.3.1.6 Rest of Europe

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Clinipace Worldwide

      2. 6.1.2 Eli Lilly and Company

      3. 6.1.3 ICON PLC

      4. 6.1.4 Novo Nordisk

      5. 6.1.5 Parexel

      6. 6.1.6 Pfizer Inc.

      7. 6.1.7 Pharmaceutical Product Development LLC

      8. 6.1.8 IQVIA

      9. 6.1.9 F. Hoffmann-La Roche AG

      10. 6.1.10 Sanofi

  7. *List Not Exhaustive
  8. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Related Reports